Cargando…

STAT3 Targets Suggest Mechanisms of Aggressive Tumorigenesis in Diffuse Large B-Cell Lymphoma

The signal transducer and activator of transcription 3 (STAT3) is a transcription factor that, when dysregulated, becomes a powerful oncogene found in many human cancers, including diffuse large B-cell lymphoma. Diffuse large B-cell lymphoma is the most common form of non-Hodgkin’s lymphoma and has...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hardee, Jennifer, Ouyang, Zhengqing, Zhang, Yuping, Kundaje, Anshul, Lacroute, Philippe, Snyder, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Genetics Society of America 2013
Materias:	Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852380/ https://www.ncbi.nlm.nih.gov/pubmed/24142927 http://dx.doi.org/10.1534/g3.113.007674

Ejemplares similares

Large-Scale Quality Analysis of Published ChIP-seq Data
por: Marinov, Georgi K., et al.
Publicado: (2013)

Anterior Pituitary Transcriptome Suggests Differences in ACTH Release in Tame and Aggressive Foxes
por: Hekman, Jessica P., et al.
Publicado: (2018)

A Patient With Regressed Diffuse Large B-Cell Lymphoma and Aggressive Follicular Lymphoma
por: Sethi, Ashish K, et al.
Publicado: (2021)

Viral Agents as Potential Drivers of Diffuse Large B-Cell Lymphoma Tumorigenesis
por: Bilajac, Esma, et al.
Publicado: (2022)

Association of Occupational Pesticide Exposure With Immunochemotherapy Response and Survival Among Patients With Diffuse Large B-Cell Lymphoma
por: Lamure, Sylvain, et al.
Publicado: (2019)

Glycoprotein PTGDS promotes tumorigenesis of diffuse large B-cell lymphoma by MYH9-mediated regulation of Wnt–β-catenin–STAT3 signaling
por: Hu, Shunfeng, et al.
Publicado: (2021)

Stem cell characteristics promote aggressiveness of diffuse large B-cell lymphoma
por: Chang, Kung-Chao, et al.
Publicado: (2020)

STAT-3 RNAscope Determination in Human Diffuse Large B-Cell Lymphoma()
por: Tamma, Roberto, et al.
Publicado: (2019)

The Search for Surrogate Endpoints in Trials in Diffuse Large B‐Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project
por: Sargent, Daniel J., et al.
Publicado: (2017)

STAT3-coordinated migration facilitates the dissemination of diffuse large B-cell lymphomas
por: Pan, Yi-Ru, et al.
Publicado: (2018)

Correlation of Global MicroRNA Expression With Basal Cell Carcinoma Subtype
por: Heffelfinger, Christopher, et al.
Publicado: (2012)

Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Choe, Jee H., et al.
Publicado: (2022)

The Dose Dependent Effects of Ruxolitinib on the Invasion and Tumorigenesis in Gliomas Cells via Inhibition of Interferon Gamma-Depended JAK/STAT Signaling Pathway
por: Delen, Emre, et al.
Publicado: (2020)

STAT3 Expression and Activity are Up‐Regulated in Diffuse Large B Cell Lymphoma of Dogs
por: Assumpção, A.L.F.V., et al.
Publicado: (2017)

Diffuse Large B-Cell Lymphoma’s New Genomics: The Bridge and the Chasm
por: Crombie, Jennifer L., et al.
Publicado: (2020)

PHOSPHO1 Serves as a Key Metabolism-Related Biomarker in the Tumorigenesis of Diffuse Large B-cell Lymphoma
por: Chen, Tian-rui, et al.
Publicado: (2022)

Spontaneous ileal perforation in a critically ill adult with aggressive diffuse large B-cell lymphomas
por: Shaaban, Hamid S., et al.
Publicado: (2013)

CD4-positive diffuse large B-cell lymphoma: A variant with aggressive clinical potential
por: Hussaini, Mohammad O, et al.
Publicado: (2016)

High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma
por: ZL, Wu, et al.
Publicado: (2011)

The Lsktm1 Locus Modulates Lung and Skin Tumorigenesis in the Mouse
por: Galvan, Antonella, et al.
Publicado: (2012)

CCDC50, an essential driver involved in tumorigenesis, is a potential severity marker of diffuse large B cell lymphoma
por: Gong, Yuqi, et al.
Publicado: (2023)

Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma
por: Lyman, Gary H., et al.
Publicado: (2020)

Aggressive CD5-Positive Primary Bone Marrow Diffuse Large B-Cell Lymphoma with Leukemic Presentation
por: Evans, Mark G., et al.
Publicado: (2021)

A Novel Missense (M206K) STAT3 Mutation in Diffuse Large B Cell Lymphoma Deregulates STAT3 Signaling
por: Hu, Guangzhen, et al.
Publicado: (2013)

Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma: An Underrecognized Aggressive Lymphoma
por: Morgan, Elizabeth A., et al.
Publicado: (2012)

Genetic polymorphisms of STAT3 correlated with prognosis in diffuse large B-cell lymphoma patients treated with rituximab
por: Hu, Yunfei, et al.
Publicado: (2014)

Ratios of Four STAT3 Splice Variants in Human Eosinophils and Diffuse Large B Cell Lymphoma Cells
por: Turton, Keren B., et al.
Publicado: (2015)

Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma
por: Kwon, Hyun Jung, et al.
Publicado: (2018)

Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma
por: Zhou, Xiangxiang, et al.
Publicado: (2020)

STAT1 and STAT3 in tumorigenesis: A matter of balance
por: Avalle, Lidia, et al.
Publicado: (2012)

Genetic and epigenetic determinants of diffuse large B-cell lymphoma
por: Bakhshi, Tanner J., et al.
Publicado: (2020)

Auxin-Inducible Depletion of the Essentialome Suggests Inhibition of TORC1 by Auxins and Inhibition of Vrg4 by SDZ 90-215, a Natural Antifungal Cyclopeptide
por: Snyder, Nathan A., et al.
Publicado: (2019)

Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent
por: Mondello, Patrizia, et al.
Publicado: (2016)

Impact of age and socioeconomic status on treatment and survival from aggressive lymphoma: a UK population-based study of diffuse large B-cell lymphoma
por: Smith, Alexandra, et al.
Publicado: (2015)

DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes
por: Kizhakeyil, Atish, et al.
Publicado: (2021)

High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients
por: Marino, Dario, et al.
Publicado: (2022)

Prognostic implication of leucocyte subpopulations in diffuse large B-cell lymphoma
por: Han, Xiao, et al.
Publicado: (2017)

GWAS of Follicular Lymphoma Reveals Allelic Heterogeneity at 6p21.32 and Suggests Shared Genetic Susceptibility with Diffuse Large B-cell Lymphoma
por: Smedby, Karin E., et al.
Publicado: (2011)

Subjective aggression during alcohol and cannabis intoxication before and after aggression exposure
por: De Sousa Fernandes Perna, E. B., et al.
Publicado: (2016)

Inhibition of the STAT3 target SGK1 sensitizes diffuse large B cell lymphoma cells to AKT inhibitors
por: Lu, Li, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_02d75mo1ifu24d6qaurnevo7ke